Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Celiac Disease: Against the Grain in Gastroenterology.

Zhu J, Mulder CJJ, Dieleman LA.

J Can Assoc Gastroenterol. 2019 Dec;2(4):161-169. doi: 10.1093/jcag/gwy042. Epub 2018 Jul 18.

2.

The Gut Microbiota in Celiac Disease and probiotics.

Chibbar R, Dieleman LA.

Nutrients. 2019 Oct 5;11(10). pii: E2375. doi: 10.3390/nu11102375. Review.

3.

Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study.

Shim HH, Ma C, Kotze PG, Seow CH, Al-Farhan H, Al-Darmaki AK, Pang JXQ, Fedorak RN, Devlin SM, Dieleman LA, Kaplan GG, Novak KL, Kroeker KI, Halloran BP, Panaccione R.

J Can Assoc Gastroenterol. 2018 Sep;1(3):115-123. doi: 10.1093/jcag/gwy013. Epub 2018 May 10.

4.

Diet in the Pathogenesis and Management of Ulcerative Colitis; A Review of Randomized Controlled Dietary Interventions.

Keshteli AH, Madsen KL, Dieleman LA.

Nutrients. 2019 Jun 30;11(7). pii: E1498. doi: 10.3390/nu11071498. Review.

5.

Surveys of parents and clinicians concerning the minimally important difference of probiotic therapy for prevention of paediatric antibiotic-associated diarrhoea.

Khanpour Ardestani S, Robinson JL, Dieleman LA, Huynh HQ, Jou H, Vohra S.

BMJ Open. 2019 Apr 2;9(4):e024651. doi: 10.1136/bmjopen-2018-024651.

6.

Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply.

Keshteli AH, Madsen KL, Mandal R, Boeckxstaens GE, Bercik P, De Palma G, Reed DE, Wishart D, Vanner S, Dieleman LA.

Aliment Pharmacol Ther. 2019 Apr;49(8):1088-1089. doi: 10.1111/apt.15200. No abstract available.

PMID:
30920043
7.

Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers.

Keshteli AH, Madsen KL, Mandal R, Boeckxstaens GE, Bercik P, De Palma G, Reed DE, Wishart D, Vanner S, Dieleman LA.

Aliment Pharmacol Ther. 2019 Mar;49(6):723-732. doi: 10.1111/apt.15141. Epub 2019 Jan 31.

PMID:
30706502
8.

Host immunoglobulin G selectively identifies pathobionts in pediatric inflammatory bowel diseases.

Armstrong H, Alipour M, Valcheva R, Bording-Jorgensen M, Jovel J, Zaidi D, Shah P, Lou Y, Ebeling C, Mason AL, Lafleur D, Jerasi J, Wong GK, Madsen K, Carroll MW, Huynh HQ, Dieleman LA, Wine E.

Microbiome. 2019 Jan 3;7(1):1. doi: 10.1186/s40168-018-0604-3.

9.

The Profile of Human Milk Metabolome, Cytokines, and Antibodies in Inflammatory Bowel Diseases Versus Healthy Mothers, and Potential Impact on the Newborn.

Meng X, Dunsmore G, Koleva P, Elloumi Y, Wu RY, Sutton RT, Ambrosio L, Hotte N, Nguyen V, Madsen KL, Dieleman LA, Chen H, Huang V, Elahi S.

J Crohns Colitis. 2019 Mar 30;13(4):431-441. doi: 10.1093/ecco-jcc/jjy186.

10.

Inulin-type fructans improve active ulcerative colitis associated with microbiota changes and increased short-chain fatty acids levels.

Valcheva R, Koleva P, Martínez I, Walter J, Gänzle MG, Dieleman LA.

Gut Microbes. 2019;10(3):334-357. doi: 10.1080/19490976.2018.1526583. Epub 2018 Nov 5.

11.

Lower Abundance and Impaired Function of CD71+ Erythroid Cells in Inflammatory Bowel Disease Patients During Pregnancy.

Dunsmore G, Koleva P, Ghobakhloo N, Sutton R, Ambrosio L, Meng X, Hotte N, Nguyen V, Madsen KL, Dieleman LA, Huang V, Elahi S.

J Crohns Colitis. 2019 Feb 1;13(2):230-244. doi: 10.1093/ecco-jcc/jjy147.

12.

Endospore forming bacteria may be associated with maintenance of surgically-induced remission in Crohn's disease.

Laffin MR, Perry T, Park H, Gillevet P, Sikaroodi M, Kaplan GG, Fedorak RN, Kroeker K, Dieleman LA, Dicken B, Madsen KL.

Sci Rep. 2018 Jun 27;8(1):9734. doi: 10.1038/s41598-018-28071-z.

13.

A Distinctive Urinary Metabolomic Fingerprint Is Linked With Endoscopic Postoperative Disease Recurrence in Crohn's Disease Patients.

Keshteli AH, Tso R, Dieleman LA, Park H, Kroeker KI, Jovel J, Gillevet PM, Sikaroodi M, Mandal R, Fedorak RN, Madsen KL.

Inflamm Bowel Dis. 2018 Mar 19;24(4):861-870. doi: 10.1093/ibd/izx070.

PMID:
29562272
14.

FUT2 genotype and secretory status are not associated with fecal microbial composition and inferred function in healthy subjects.

Turpin W, Bedrani L, Espin-Garcia O, Xu W, Silverberg MS, Smith MI, Guttman DS, Griffiths A, Moayyedi P, Panaccione R, Huynh H, Steinhart H, Aumais G, Shestopaloff K, Dieleman LA, Turner D, Paterson AD, Croitoru K.

Gut Microbes. 2018 Jul 4;9(4):357-368. doi: 10.1080/19490976.2018.1445956. Epub 2018 Apr 27.

15.

The NOD2-Smoking Interaction in Crohn's Disease is likely Specific to the 1007fs Mutation and may be Explained by Age at Diagnosis: A Meta-Analysis and Case-Only Study.

Kuenzig ME, Yim J, Coward S, Eksteen B, Seow CH, Barnabe C, Barkema HW, Silverberg MS, Lakatos PL, Beck PL, Fedorak R, Dieleman LA, Madsen K, Panaccione R, Ghosh S, Kaplan GG.

EBioMedicine. 2017 Jul;21:188-196. doi: 10.1016/j.ebiom.2017.06.012. Epub 2017 Jun 16. Review.

16.

Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study.

Ma C, Lumb R, Walker EV, Foshaug RR, Dang TT, Verma S, Huang VW, Kroeker KI, Wong K, Dieleman LA, Fedorak RN, Halloran BP.

Inflamm Bowel Dis. 2017 Sep;23(9):1643-1649. doi: 10.1097/MIB.0000000000001173.

PMID:
28644184
17.

Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study.

Keshteli AH, van den Brand FF, Madsen KL, Mandal R, Valcheva R, Kroeker KI, Han B, Bell RC, Cole J, Hoevers T, Wishart DS, Fedorak RN, Dieleman LA.

World J Gastroenterol. 2017 Jun 7;23(21):3890-3899. doi: 10.3748/wjg.v23.i21.3890.

18.

Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study.

Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N, Kroeker KI, Seow CH, Leung Y, Novak KL, Halloran BP, Huang VW, Wong K, Blustein PK, Ghosh S, Panaccione R.

Inflamm Bowel Dis. 2017 May;23(5):833-839. doi: 10.1097/MIB.0000000000001074.

PMID:
28328624
19.

Increased Intestinal Permeability in Relatives of Patients With Crohn's Disease Is Not Associated With Small Bowel Ulcerations.

Teshima CW, Goodman KJ, El-Kalla M, Turk S, El-Matary W, Valcheva R, Danchak R, Gordon M, Ho P, Mullins A, Wong D, Kao D, Meddings J, Huynh H, Dieleman LA.

Clin Gastroenterol Hepatol. 2017 Sep;15(9):1413-1418.e1. doi: 10.1016/j.cgh.2017.02.028. Epub 2017 Mar 7.

PMID:
28286191
20.

Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.

Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N, Kroeker KI, Seow CH, Leung Y, Novak KL, Halloran BP, Huang VW, Wong K, Blustein PK, Ghosh S, Panaccione R.

Aliment Pharmacol Ther. 2017 May;45(9):1232-1243. doi: 10.1111/apt.14016. Epub 2017 Mar 2.

21.

AGY, a Novel Egg Yolk-Derived Anti-gliadin Antibody, Is Safe for Patients with Celiac Disease.

Sample DA, Sunwoo HH, Huynh HQ, Rylance HL, Robert CL, Xu BW, Kang SH, Gujral N, Dieleman LA.

Dig Dis Sci. 2017 May;62(5):1277-1285. doi: 10.1007/s10620-016-4426-5. Epub 2016 Dec 29.

PMID:
28035551
22.

Within-Stool and Within-Day Sample Variability of Fecal Calprotectin in Patients With Inflammatory Bowel Disease: A Prospective Observational Study.

Du L, Foshaug R, Huang VW, Kroeker KI, Dieleman LA, Halloran BP, Wong K, Fedorak RN.

J Clin Gastroenterol. 2018 Mar;52(3):235-240. doi: 10.1097/MCG.0000000000000776.

PMID:
28009684
23.

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.

Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI–IM-UNITI Study Group.

N Engl J Med. 2016 Nov 17;375(20):1946-1960.

24.

Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding Varies Widely: A Need for Further Education.

Huang VW, Chang HJ, Kroeker KI, Goodman KJ, Hegadoren KM, Dieleman LA, Fedorak RN.

Can J Gastroenterol Hepatol. 2016;2016:6193275. Epub 2016 Sep 20.

25.

Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study.

Ma C, Beilman CL, Huang VW, Fedorak DK, Wong K, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN.

Can J Gastroenterol Hepatol. 2016;2016:2079582. doi: 10.1155/2016/2079582. Epub 2016 Jul 11.

26.

Probiotics and prebiotics in ulcerative colitis.

Derikx LA, Dieleman LA, Hoentjen F.

Best Pract Res Clin Gastroenterol. 2016 Feb;30(1):55-71. doi: 10.1016/j.bpg.2016.02.005. Epub 2016 Feb 9. Review.

PMID:
27048897
27.

Prebiotics: Definition and protective mechanisms.

Valcheva R, Dieleman LA.

Best Pract Res Clin Gastroenterol. 2016 Feb;30(1):27-37. doi: 10.1016/j.bpg.2016.02.008. Epub 2016 Feb 18. Review.

PMID:
27048894
28.

Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study.

Ma C, Beilman CL, Huang VW, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN.

Inflamm Bowel Dis. 2016 Apr;22(4):870-9. doi: 10.1097/MIB.0000000000000679.

PMID:
26818419
29.

Mucosal Barrier Depletion and Loss of Bacterial Diversity are Primary Abnormalities in Paediatric Ulcerative Colitis.

Alipour M, Zaidi D, Valcheva R, Jovel J, Martínez I, Sergi C, Walter J, Mason AL, Wong GK, Dieleman LA, Carroll MW, Huynh HQ, Wine E.

J Crohns Colitis. 2016 Apr;10(4):462-71. doi: 10.1093/ecco-jcc/jjv223. Epub 2015 Dec 9.

30.

Recommendations for Probiotic Use--2015 Update: Proceedings and Consensus Opinion.

Floch MH, Walker WA, Sanders ME, Nieuwdorp M, Kim AS, Brenner DA, Qamar AA, Miloh TA, Guarino A, Guslandi M, Dieleman LA, Ringel Y, Quigley EM, Brandt LJ.

J Clin Gastroenterol. 2015 Nov-Dec;49 Suppl 1:S69-73. doi: 10.1097/MCG.0000000000000420. Erratum in: J Clin Gastroenterol. 2016 Oct;50(9):800.

PMID:
26447969
31.

Probiotics in the Management of Ulcerative Colitis.

Chibbar R, Dieleman LA.

J Clin Gastroenterol. 2015 Nov-Dec;49 Suppl 1:S50-5. doi: 10.1097/MCG.0000000000000368. Review.

PMID:
26447965
32.

Inflammatory bowel disease patients are frequently nonadherent to scheduled induction and maintenance infliximab therapy: A Canadian cohort study.

Ma C, Evaschesen CJ, Gracias G, Huang VW, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN.

Can J Gastroenterol Hepatol. 2015 Aug-Sep;29(6):309-14. Epub 2015 Jun 12.

33.

Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy.

Huang VW, Prosser C, Kroeker KI, Wang H, Shalapay C, Dhami N, Fedorak DK, Halloran B, Dieleman LA, Goodman KJ, Fedorak RN.

Inflamm Bowel Dis. 2015 Jun;21(6):1359-67. doi: 10.1097/MIB.0000000000000376.

34.

Does the level of reproductive knowledge specific to inflammatory bowel disease predict childlessness among women with inflammatory bowel disease?

Huang VW, Chang HJ, Kroeker KI, Goodman KJ, Hegadoren KM, Dieleman LA, Fedorak RN.

Can J Gastroenterol Hepatol. 2015 Mar;29(2):95-103.

35.

A study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels.

Huang V, Dhami N, Fedorak D, Prosser C, Shalapay C, Kroeker KI, Halloran BP, Dieleman LA, Fedorak RN.

Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):35-40.

36.

The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease.

Fedorak RN, Feagan BG, Hotte N, Leddin D, Dieleman LA, Petrunia DM, Enns R, Bitton A, Chiba N, Paré P, Rostom A, Marshall J, Depew W, Bernstein CN, Panaccione R, Aumais G, Steinhart AH, Cockeram A, Bailey RJ, Gionchetti P, Wong C, Madsen K.

Clin Gastroenterol Hepatol. 2015 May;13(5):928-35.e2. doi: 10.1016/j.cgh.2014.10.031. Epub 2014 Nov 6.

PMID:
25460016
37.

Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.

Ma C, Huang V, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN.

J Clin Gastroenterol. 2015 Sep;49(8):675-82. doi: 10.1097/MCG.0000000000000265.

PMID:
25389599
38.

Chemically defined diet alters the protective properties of fructo-oligosaccharides and isomalto-oligosaccharides in HLA-B27 transgenic rats.

Koleva P, Ketabi A, Valcheva R, Gänzle MG, Dieleman LA.

PLoS One. 2014 Nov 4;9(11):e111717. doi: 10.1371/journal.pone.0111717. eCollection 2014.

39.

Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease.

Ma C, Huang V, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN.

Aliment Pharmacol Ther. 2014 Nov;40(9):1044-55. doi: 10.1111/apt.12940. Epub 2014 Sep 3.

40.

Clostridium difficile infection worsens the prognosis of ulcerative colitis.

Negrón ME, Barkema HW, Rioux K, De Buck J, Checkley S, Proulx MC, Frolkis A, Beck PL, Dieleman LA, Panaccione R, Ghosh S, Kaplan GG.

Can J Gastroenterol Hepatol. 2014 Jul-Aug;28(7):373-80.

41.

Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.

Ma C, Huang V, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN.

J Crohns Colitis. 2014 Nov;8(11):1454-63. doi: 10.1016/j.crohns.2014.05.007. Epub 2014 Jun 16.

PMID:
24947334
42.

Routine colonoscopy is not required in uncomplicated diverticulitis: a systematic review.

de Vries HS, Boerma D, Timmer R, van Ramshorst B, Dieleman LA, van Westreenen HL.

Surg Endosc. 2014 Jul;28(7):2039-47. doi: 10.1007/s00464-014-3447-4. Epub 2014 Feb 1. Review.

PMID:
24488358
43.

Phenotypic features of Crohn's disease associated with failure of medical treatment.

Moran GW, Dubeau MF, Kaplan GG, Yang H, Seow CH, Fedorak RN, Dieleman LA, Barkema HW, Ghosh S, Panaccione R; Alberta Inflammatory Bowel Disease Consortium.

Clin Gastroenterol Hepatol. 2014 Mar;12(3):434-42.e1. doi: 10.1016/j.cgh.2013.08.026. Epub 2013 Aug 24.

PMID:
23978351
44.

Environment and the inflammatory bowel diseases.

Frolkis A, Dieleman LA, Barkema HW, Panaccione R, Ghosh S, Fedorak RN, Madsen K, Kaplan GG; Alberta IBD Consortium.

Can J Gastroenterol. 2013 Mar;27(3):e18-24. Review.

45.

Increased epithelial gaps in the small intestine are predictive of hospitalization and surgery in patients with inflammatory bowel disease.

Turcotte JF, Wong K, Mah SJ, Dieleman LA, Kao D, Kroeker K, Claggett B, Saltzman JR, Wine E, Fedorak RN, Liu JJ.

Clin Transl Gastroenterol. 2012 Jul 26;3:e19. doi: 10.1038/ctg.2012.13.

46.

Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation.

Lu C, Waugh A, Bailey RJ, Cherry R, Dieleman LA, Gramlich L, Matic K, Millan M, Kroeker KI, Sadowski D, Teshima CW, Todoruk D, Wong C, Wong K, Fedorak RN.

World J Gastroenterol. 2012 Sep 28;18(36):5058-64. doi: 10.3748/wjg.v18.i36.5058.

47.

Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats.

Lin XB, Dieleman LA, Ketabi A, Bibova I, Sawyer MB, Xue H, Field CJ, Baracos VE, Gänzle MG.

PLoS One. 2012;7(7):e39764. doi: 10.1371/journal.pone.0039764. Epub 2012 Jul 26.

48.

Abnormal intestinal permeability in Crohn's disease pathogenesis.

Teshima CW, Dieleman LA, Meddings JB.

Ann N Y Acad Sci. 2012 Jul;1258:159-65. doi: 10.1111/j.1749-6632.2012.06612.x.

PMID:
22731729
49.

Patients with inflammatory bowel disease exhibit dysregulated responses to microbial DNA.

Hotte NS, Salim SY, Tso RH, Albert EJ, Bach P, Walker J, Dieleman LA, Fedorak RN, Madsen KL.

PLoS One. 2012;7(5):e37932. doi: 10.1371/journal.pone.0037932. Epub 2012 May 23.

50.

Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease.

Guo B, Harstall C, Louie T, Veldhuyzen van Zanten S, Dieleman LA.

Aliment Pharmacol Ther. 2012 Apr;35(8):865-75. doi: 10.1111/j.1365-2036.2012.05033.x. Epub 2012 Feb 23. Review.

Supplemental Content

Loading ...
Support Center